BioLife Solutions Earnings Call Transcripts
Fiscal Year 2026
-
Stockholders approved the merger agreement with Repligen, along with the advisory compensation and adjournment proposals. The two-step transaction would leave the surviving entity as a direct wholly-owned Repligen subsidiary.
-
Q1 2026 revenue rose 25% year-over-year to $27.5M, led by BPM demand, with adjusted EBITDA up 15%. Guidance for 2026 revenue of $112.5–$115M and margin expansion was reaffirmed, as operational improvements and new product launches are expected to drive growth.
Fiscal Year 2025
-
Delivered 29% revenue growth and margin expansion in 2025, driven by commercial BPM customers and portfolio optimization. 2026 guidance calls for 17–20% revenue growth, positive GAAP net income, and continued margin improvement, with growth led by commercial demand.
-
Q3 revenue grew 31% year-over-year, driven by strong cell processing sales and margin expansion. Full-year guidance was raised following the sale of the evo Cold Chain business, with commercial and late-stage clinical customers expected to drive future growth.
-
Q2 2025 saw 29% revenue growth, led by cell processing, and expanded adjusted EBITDA margin. Full-year guidance was raised, with strong visibility into second-half demand and continued investment in strategic growth initiatives.
-
Q1 2025 saw 30% revenue growth and a significant margin expansion, driven by strong cell processing sales and operational leverage. Guidance for 2025 was reaffirmed, with continued growth expected and minimal impact from industry headwinds.
Fiscal Year 2024
-
2024 saw a strategic transformation with divestitures boosting margins and cash, while cell processing revenue hit record highs. 2025 guidance projects 16–20% revenue growth, margin expansion, and increased R&D, with growth driven by commercial therapy customers and cross-selling initiatives.
-
Q3 2024 saw strong sequential and year-over-year revenue growth, margin expansion, and a narrowed net loss, driven by robust cell processing sales and the strategic divestiture of SciSafe. Updated guidance reflects increased cell processing expectations and continued focus on high-margin recurring revenue streams.
-
Sequential revenue growth in cell processing and improved margins followed the divestiture of freezer businesses. Full-year guidance was raised, with strong performance in biopreservation media and new product launches like CryoCase supporting future growth.